MetaCap

Boundless Bio (BOLD) vs Citius Oncology (CTOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed Citius Oncology (CTOR) over the past year, gaining 105.3% versus a loss of 55.4%. Boundless Bio is the larger company by market cap ($54.8 million vs $53.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%CTOR-55.44%
+177%+55%-67%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%CTOR-95.45%
+284%+85%-114%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus CTOR key metrics
MetricBOLDCTOR
Share price$2.32$0.5035
Market cap$54.78M$53.25M
1-day change-2.52%-10.95%
YTD return+93.33%-49.65%
1-year return+105.31%-55.44%
EPS (TTM)$-2.46$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-58.20M$-24.76M
52-week high$3.16$1.83
52-week low$0.961$0.491
Distance from 52-week high-26.68%-72.49%
Analyst consensusnonenone
Avg. price target upside+72.41%+694.44%
Average volume131.34K114.02K
Shares outstanding23.61M105.76M
Employees28—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed CTOR by 160.8 percentage points over the past year.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Citius Oncology

CTOR stock →

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations

BOLD vs CTOR FAQ

Which is bigger, Boundless Bio or Citius Oncology?

Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $53.25M for Citius Oncology (CTOR).

Which stock has performed better over the past year, BOLD or CTOR?

BOLD returned +105.31% over the past 12 months, compared with -55.44% for CTOR (price return, excluding dividends). Past performance does not predict future results.

Are Boundless Bio and Citius Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons